Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Thomas Powles, Laurence Albiges, Katriina Johanna Jalkanen, Guillermo De Velasco, Mauricio Burotto, Pooja Ghatalia, Cristina Suárez, Elaine T. Lam, Roberto Iacovelli, Mahmut Gumus, Elena Verzoni, Christian K. Kollmannsberger, Walter Michael Stadler, Balaji Venugopal, Reshma Shinde, Todd L. Saretsky, Li He, Donna Vickery, Toni K. Choueiri, Brian I. Rini
Institutions: Queen Mary University of London, Cancer Research UK, Barts Cancer Institute, Université Paris-Saclay, Institut Gustave Roussy, Helsinki University Hospital, Hospital Universitario 12 De Octubre, Fox Chase Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Colorado Cancer Center, Agostino Gemelli University Polyclinic, Istanbul Medeniyet University, Fondazione IRCCS Istituto Nazionale dei Tumori, BC Cancer Agency, University of Chicago, Beatson West of Scotland Cancer Centre, University of Glasgow, Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute, Vanderbilt University Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4391303209